Resource Logo
AIDS Weekly Plus

Reports on HIV/AIDS Findings from University Health Network Provide New Insights




 



2012 DEC 3 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Investigators discuss new findings in Immune System Diseases and Conditions. According to news reporting originating in Toronto, Canada, by NewsRx journalists, research stated, "To characterize persons undergoing HIV genotypic resistance testing (GRT) while treatment naive and to estimate the prevalence of transmitted HIV drug resistance (TDR) among HIV-positive outpatients in Ontario, Canada. We analysed data from a multi-site cohort of persons receiving HIV care."

The news reporters obtained a quote from the research from University Health Network, "Data were obtained from medical chart abstractions, interviews and record linkage with the Public Health Laboratories, Public Health Ontario. The analysis was restricted to 626 treatment-naive persons diagnosed in 200209. TDR mutations were identified using the calibrated population resistance tool. We used descriptive statistics and regression methods to characterize treatment-naive GRT test uptake and patterns of TDR. Overall, 53.2 (333/626) of participants had baseline GRT. The proportion increased with year of HIV diagnosis from 30.0 in 2002 to 82.6 in 2009 (P0.0001). Among those tested, 13.6 (CI 9.917.3) had one or more drug resistance mutations, and 8.8 (CI 5.711.8), 4.8 (CI 2.57.2) and 2.7 (CI 1.04.5) had mutations conferring resistance to nucleoside/tide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs), respectively. TDR prevalence increased from 200207 to 200809 (adjusted OR 3.7, 95 CI 1.78.2), driven by a higher proportion with NRTI (18.2 versus 5.9, P0.0009) and NNRTI mutations (11.7 versus 2.8, P0.004) in the later time period. PI TDR remained unchanged. Baseline GRT increased dramatically since 2002, but remains below 100. The prevalence of overall TDR tripled due to increases in NRTI and NNRTI mutations."

According to the news reporters, the research concluded: "These findings highlight the value of routine baseline GRT for TDR surveillance and patient care."

For more information on this research see: Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 200209. Journal of Antimicrobial Chemotherapy, 2012;67(11):2755-2765. Journal of Antimicrobial Chemotherapy can be contacted at: Oxford Univ Press, Great Clarendon St, Oxford OX2 6DP, England. (Oxford University Press - www.oup.com/; Journal of Antimicrobial Chemotherapy - jac.oxfordjournals.org)

Our news correspondents report that additional information may be obtained by contacting A.N. Burchell, Mt. Sinai Hospital, Univ Hlth Network, Toronto, ON M5G 1X5, Canada (see also Immune System Diseases and Conditions).

Keywords for this news article include: Canada, Toronto, Ontario, Genetics, HIV/AIDS, RNA Viruses, AIDS Therapy, Retroviridae, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, North and Central America, Viral Sexually Transmitted Diseases, Immune System Diseases and Conditions

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2012, NewsRx LLC



 


Copyright © 2012 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in December 3, 2012. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.